Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resimmune in Mycosis Fungoides
NCT02943642Phase 2Withdrawn
- Sponsor
- Virogen Biotechnology
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Immunotoxins, Peptides, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of A-dmDT390-bisFv(UCHT1) in mycosis fungoides (MF) (3 arms), sponsored by Virogen Biotechnology. Primary endpoint: Incidence of Complete Responses at 12 months. Planned start May 2026; status: withdrawn.
02
Drugs
A-dmDT390-bisFv(UCHT1)
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT02943642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943642.